Literature DB >> 10829053

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.

P C Trask1, P Esper, M Riba, B Redman.   

Abstract

The increasing use of interferon (IFN) in treating a variety of disorders including, malignant melanoma and hepatitis C, has resulted in the identification and increasing concern about the psychiatric side effects that can result from treatment. These effects can occur either shortly after beginning IFN therapy or later as a result of continued treatment. Studies have reported the incidence of later side effects, which include symptoms of depression, anxiety, and occasional suicidal ideation, to be from 0% to 70%. Case studies have demonstrated that pharmacologic interventions are beneficial in reducing iatrogenic psychiatric symptoms while allowing patients to maintain IFN therapy. The present article provides an overview of the psychiatric effects of IFN therapy, the proposed mechanisms of these side effects, and case studies that provide mechanistic support. In addition, limitations of the current literature are provided with suggestions for treating physicians and a discussion of possible future research directions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10829053     DOI: 10.1200/JCO.2000.18.11.2316

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  44 in total

1.  The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.

Authors:  J Bacik; M Mazumdar; B A Murphy; D L Fairclough; S Eremenco; T Mariani; R J Motzer; D Cella
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

Review 2.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

3.  Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism.

Authors:  Francis E Lotrich; Robert E Ferrell; Mordechai Rabinovitz; Bruce G Pollock
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 4.  Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.

Authors:  Xiao-Min Wang; Brian Walitt; Leorey Saligan; Agnes F Y Tiwari; Chi Wai Cheung; Zhang-Jin Zhang
Journal:  Cytokine       Date:  2015-01-05       Impact factor: 3.861

5.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

6.  Negative regulation of human astrocytes by interferon (IFN) α in relation to growth inhibition and impaired glucose utilization.

Authors:  Ting Wang; Yasuhiro Takikawa; Kei Sawara; Yuichi Yoshida; Kazuyuki Suzuki
Journal:  Neurochem Res       Date:  2012-05-25       Impact factor: 3.996

Review 7.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

Review 8.  Toxoplasma gondii infection and behaviour - location, location, location?

Authors:  Glenn A McConkey; Heather L Martin; Greg C Bristow; Joanne P Webster
Journal:  J Exp Biol       Date:  2013-01-01       Impact factor: 3.312

Review 9.  Role of the psychiatrist in the care of patients with hepatitis C and HIV/AIDS.

Authors:  Stephen Price; Juanita Goyette
Journal:  Psychiatr Q       Date:  2003

10.  A comparison of modified directly observed therapy to standard care for chronic hepatitis C.

Authors:  Patricia A Cioe; Michael D Stein; Kittichai Promrat; Peter D Friedmann
Journal:  J Community Health       Date:  2013-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.